Emergency Penicillin Shortage Lets a Pregnant Woman Miss Life‑Saving Treatment

A pregnant woman in Gila County, Arizona, was diagnosed with syphilis at the end of March. The disease can cause severe harm to a baby if untreated, including early delivery, miscarriage or serious birth defects. The only approved drug in the United States for treating pregnant patients is an injectable penicillin sold by Pfizer as Bicillin L‑A. Since July 2025, the nation has faced a shortage of this medicine.

Pfizer had an emergency request protocol for situations like this, but the system fell short. On March 27 a public‑health office submitted an urgent request; Pfizer acknowledged it on the following Monday. Still, by April 7 the medication had not arrived. A representative from the National Coalition of STD Directors asked Pfizer how to expedite delivery, but a response came too late. By the time the exchange happened, the patient had already given birth and the opportunity to prevent congenital syphilis was lost.

In February, the coalition had asked Pfizer to donate a portion of its Bicillin L‑A supply to state health departments as an emergency reserve. Pfizer had not complied, and in June it said it was still weighing the idea of sending out doses ahead of time. This Arizona case showed why that proposal had been made in the first place: a critical shortage can turn a life‑saving drug into an unavailable commodity.

The incident highlights gaps in emergency drug distribution and the need for better contingency plans to protect vulnerable patients.